In July 2024, the Clinical Trials Function of Ghana’s Food and Drugs Authority (FDA) was assessed at Maturity Level 4 (ML4) under the World Health Organization’s Global Benchmarking Tool (GBT) — the highest of the tool’s four maturity levels, and, according to the FDA’s own announcement, the first time any national regulatory authority in Africa reached ML4 specifically in the Clinical Trials Oversight function. For sponsors, CROs, and research administrators evaluating Ghana as a trial site, that rating is a useful signal of institutional capacity, but it does not change what the FDA actually requires to authorize a trial. This guide covers both: what the maturity rating means and what the authorization pathway itself requires in practice.
What WHO Maturity Level 4 Actually Means
WHO’s Global Benchmarking Tool (GBT) is the instrument WHO uses to assess national regulatory authorities against more than 260 indicators spanning core regulatory functions — marketing authorization, market surveillance, licensing, laboratory testing, vigilance, and clinical trials oversight among them. Authorities are rated on a four-level maturity scale, from Maturity Level 1 (some elements of a regulatory system exist) through Maturity Level 4 (the regulatory system operates at an advanced level of performance with a focus on continuous improvement). WHO also uses GBT results to designate authorities as WHO-Listed Authorities (WLAs) once specific reliability thresholds are met.
Ghana FDA’s broader regulatory system had already reached Maturity Level 3 (ML3) in 2018 — WHO’s Africa regional office (AFRO) recorded it at the time as the second African national regulatory authority to reach ML3, after Tanzania. The 2024 announcement is more specific: it applies to the Clinical Trials function benchmarked separately under GBT’s function-specific tracks, and it is what the FDA and Ghanaian press reporting describe as a first for any African regulator specifically in that function. Sponsors should read the claim at that precision — a function-specific ML4 rating in Clinical Trials Oversight — rather than as a claim about Ghana’s overall regulatory maturity across every GBT function, which is a related but separate assessment.
Practically, an ML4 clinical trials function tells a sponsor that Ghana FDA’s trial-authorization system has documented, functioning processes for application review, GCP inspection, safety oversight, and quality management that meet WHO’s benchmark for advanced, self-improving regulatory systems — the kind of evidence multi-country sponsors and reliance-based regulators increasingly weigh when deciding where to run early-phase or multi-site African trials.
Who Authorizes Clinical Trials in Ghana
The FDA is the statutory body responsible for authorizing the initiation and conduct of clinical trials of medicines, food supplements, vaccines, and medical devices in Ghana. Authorization from the FDA is required in addition to, not instead of, ethical review: a trial needs both FDA clinical trial authorization and approval from an accredited Ethics Committee (EC) or Institutional Review Board (IRB), such as the Ghana Health Service Ethics Review Committee or another accredited institutional EC/IRB, before enrollment can begin. The FDA’s role is the final regulatory authorization; the EC/IRB’s role is the ethical review of the protocol, informed consent materials, and participant protections. Neither substitutes for the other.
The Clinical Trial Application (CTA) Process
Sponsors apply to Ghana FDA using a Clinical Trial Application (CTA), submitted with a covering letter, the non-refundable application fee, and the FDA’s application forms signed by an authorized representative. Per the FDA’s published clinical trials authorization guidance, a complete CTA submission includes:
- The clinical trial protocol and any protocol amendments
- Proof of registration (or evidence of submission) with the Pan African Clinical Trials Registry (PACTR)
- The Investigator’s Brochure
- The Investigational Product (IP) dossier, covering quality, manufacturing, and non-clinical/clinical data supporting the IP
- A Good Manufacturing Practice (GMP) certificate for the investigational product
- Ethics Committee/IRB approval, or evidence of submission to an EC/IRB where final approval is still pending
- Evidence of insurance/indemnity coverage for trial participants
- A financial declaration covering sponsor and site financial arrangements
- Data Safety Monitoring Board (DSMB) documentation, where applicable to the trial design
- Contractual agreements between sponsor, CRO, and site(s)
- The informed consent form(s) and participant information sheets
- The statistical analysis plan
- Material transfer agreements, where biological samples will be exported or transferred
All documents must be submitted in both hard copy and soft copy (one of each), with electronic files provided as searchable PDFs. A CTA missing more than 30% of the required documentation — or missing any of the four items the FDA treats as non-negotiable minimums (application fee, signed protocol, Investigator’s Brochure, and completed application form) — is subject to outright rejection rather than a deficiency letter, so sponsors should treat the document checklist as a hard gate on submission-readiness, not a soft guideline.
The FDA’s Technical Advisory Committee — a 12-member body — provides ongoing medical and scientific advice to the FDA on clinical trial matters, including current and emerging scientific issues that bear on how applications are reviewed.
GCP and Ongoing Oversight
Ghana FDA requires trials to be conducted to ICH Good Clinical Practice (GCP) standards alongside national regulation. Beyond initial authorization, the FDA’s safety monitoring function covers pharmacovigilance for investigational products, adverse event and serious adverse event reporting, and inspection of trial conduct against the approved protocol — the ongoing oversight function that the 2024 ML4 rating specifically credits as operating at an advanced, continuously-improving standard.
Ghana FDA in Context: How It Compares to Peer African Regulators
Ghana is one of several African national regulatory authorities that have built out formal clinical trial authorization pathways over the past decade, alongside NAFDAC in Nigeria, SAHPRA in South Africa, Egypt’s EDA, and Kenya’s Pharmacy and Poisons Board. What distinguishes Ghana’s FDA in the WHO benchmarking record specifically is the July 2024 ML4 rating in the Clinical Trials Oversight function — a narrower, function-specific claim than a general statement that Ghana’s regulatory system is Africa’s most advanced across every GBT function. Sponsors comparing jurisdictions for a multi-country African trial should still evaluate each regulator’s documentation requirements, review timelines, and EC/IRB landscape individually; a strong WHO maturity rating in one function is evidence of institutional capacity, not a guarantee of a faster review clock. For sponsors planning trials across multiple African Union member states, the emerging African Medicines Agency (AMA) framework is also worth tracking, as it is intended to eventually support joint or reliance-based review across participating countries rather than requiring a fully separate national submission in each.
Ghana’s FDA clinical trial pathway is a separate function from the country’s national research-funding infrastructure; research administrators tracking Ghana more broadly should also see this site’s guide to the Ghana National Research Fund (GNRF), a distinct, newly-operational funding body rather than a regulatory authority.
Frequently Asked Questions
Is Ghana the first African country to reach WHO Maturity Level 4 overall?
No — the claim, as reported by Ghana FDA and Ghanaian press coverage, is specific to the Clinical Trials Oversight function under WHO’s Global Benchmarking Tool, achieved in July 2024. Ghana FDA’s broader regulatory system reached Maturity Level 3 in 2018, reported at the time as the second African authority (after Tanzania) to do so. Treat the ML4 claim as function-specific to clinical trials oversight, not as a claim about every regulatory function WHO benchmarks.
Does FDA authorization replace ethics committee approval in Ghana?
No. FDA clinical trial authorization and Ethics Committee/IRB approval are separate, both-required steps. The FDA accepts evidence of EC/IRB submission (rather than final approval) at the time of CTA filing in some cases, but final ethics approval remains a precondition of trial conduct.
What happens if a CTA submission is incomplete?
Ghana FDA guidance sets a document-completeness threshold: an application missing more than roughly 30% of the required documentation, or missing any of the fee, signed protocol, Investigator’s Brochure, or application form, is subject to rejection rather than a request for additional information.
Does PACTR registration need to be complete before submitting to Ghana FDA?
The FDA’s checklist calls for proof of registration with the Pan African Clinical Trials Registry (PACTR); sponsors should confirm current requirements directly with the FDA and PACTR, as registry-timing requirements are the kind of procedural detail regulators periodically update.
Sources
Primary and near-primary sources used in this guide: Ghana FDA’s Clinical Trials Authorization Service page and published clinical trials guideline documents; WHO/AFRO’s 2018 announcement on Ghana FDA attaining Maturity Level 3; and Ghanaian trade/press reporting on the July 2024 Maturity Level 4 Clinical Trials Oversight rating. Research administrators should verify current fee schedules, review timelines, and document checklists directly with Ghana FDA before submitting, as these are the details national regulators update most frequently.
